DeepMed Research

GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults

Phase 1

Completed

Conditions: Respiratory Synctial Virus Infections

Interventions: Drug: Placebo
Biological: GSK3389245A_LD GROUP
Biological: GSK3389245A_HD GROUP
Biological: Bexsero

First Posted Date: 2015-07-08

Last Posted Date: 2018-08-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 73

Registration Number: NCT02491463

Locations: 🇬🇧
GSK Investigational Site, Oxford, Oxfordshire, United Kingdom

Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France

Completed

Conditions: Herpes Zoster

Interventions: Other: Data collection

First Posted Date: 2015-07-01

Last Posted Date: 2019-09-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 106

Registration Number: NCT02487472

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults

Phase 2

Completed

Conditions: Virus Diseases

Interventions: Biological: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
Drug: Placebo

First Posted Date: 2015-06-30

Last Posted Date: 2018-01-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 3024

Registration Number: NCT02485301

Locations: 🇸🇳
GSK Investigational Site, Dakar, Senegal

Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: FF
Drug: Montelukast
Drug: Albuterol/Salbutamol

First Posted Date: 2015-06-29

Last Posted Date: 2020-04-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 111

Registration Number: NCT02483975

Locations: 🇿🇦
GSK Investigational Site, Bellville, South Africa

Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza

Phase 2

Completed

Conditions: Virus Diseases

Interventions: Drug: GSK1325756 (Danirixin)
Drug: Placebo To Match GSK1325756
Drug: Placebo To Match Oseltamivir Phosphate
Drug: Oseltamivir Phosphate

First Posted Date: 2015-06-11

Last Posted Date: 2019-07-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 45

Registration Number: NCT02469298

Locations: 🇿🇦
GSK Investigational Site, Reiger Park, South Africa

Pharmacokinetic Study of Topical GSK2894512 Cream

Phase 1

Completed

Conditions: Dermatitis, Atopic

Interventions: Drug: GSK2894512 Topical Cream

First Posted Date: 2015-06-09

Last Posted Date: 2017-05-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 11

Registration Number: NCT02466152

Locations: 🇨🇦
GSK Investigational Site, Montreal, Quebec, Canada

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Diabetes Mellitus

Interventions: Biological: Albiglutide matching placebo
Biological: Albiglutide 30 mg
Biological: Albiglutide 50 mg

First Posted Date: 2015-06-08

Last Posted Date: 2019-03-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 9463

Registration Number: NCT02465515

Locations: 🇬🇧
GSK Investigational Site, Wigan, United Kingdom

Efficacy Study of Protein Supplementation in Attenuating the Decline in Performance After Strenuous Concurrent Exercise

Not Applicable

Completed

Conditions: Sports Nutritional Sciences

Interventions: Dietary Supplement: Reference product 1
Dietary Supplement: Test product
Dietary Supplement: Reference product 2

First Posted Date: 2015-06-01

Last Posted Date: 2016-08-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT02458599

Locations: 🇬🇧
GSK Investigational Site, Brentford, United Kingdom

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Danirixin HBr 50 mg IR Tablet
Drug: Danirixin FB 50 mg IR Tablet
Drug: Prilosec (omeprazole) 40mg Delayed-Release capsule

First Posted Date: 2015-05-25

Last Posted Date: 2018-07-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT02453022

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)

Phase 2

Completed

Conditions: Infections, Meningococcal
Meningococcal Disease

Interventions: Biological: MenABCWY+OMV vaccine

First Posted Date: 2015-05-22

Last Posted Date: 2020-07-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 129

Registration Number: NCT02451514

Locations: 🇵🇦
GSK Investigational Site, Panama City, Panama

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy